[1]陈洈伟,徐丹,王艳,等.血清HE4、NGAL和CA125联合检测对子宫内膜癌的临床诊断意义[J].陕西医学杂志,2018,(11):1500-1502.
　Chen Weiwei,Xu Dan,Wang Yan,et al.Clinical diagnostic significance of combined detection of serum HE4，NGAL and CA125 for endometrial carcinoma[J].,2018,(11):1500-1502.
点击复制

血清HE4、NGAL和CA125联合检测对子宫内膜癌的临床诊断意义
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2018年11期
页码:
1500-1502
栏目:
临床检验
出版日期:
2018-11-29

文章信息/Info

Title:
Clinical diagnostic significance of combined detection of serum HE4，NGAL and CA125 for endometrial carcinoma
文章编号:
0.3969/j.issn.1000-7377.2018.11.040
作者:
陈洈伟; 徐丹; 王艳; 杨书雄; 刘新群; 林晓君
湖北省松滋市人民医院病理科（荆州 434200）
Author(s):
Chen Weiwei; Xu Dan; Wang Yan; et al.
Department of Pathology，People’s Hospital of Songzi City in Hubei Province (Jingzhou 434200)
关键词:
子宫内膜肿瘤/诊断附睾分泌蛋白质类/血液CA-125抗原/血液@中性粒细胞明胶酶相关脂质载运蛋白
Keywords:
Endometrial neoplasms/diagnosis Epididymal secretory proteins/bloodCA-125 antigen/blood@Neutrophil gelatinase related lipid carrier protein
分类号:
R737.33
文献标志码:
A
摘要:
目的：探讨血清人附睾分泌蛋白E4（HE4）、中性粒细胞明胶酶相关脂质载运蛋白（NGAL）和人卵巢癌抗原（CA125）联合检测在子宫内膜癌（EC）中的临床诊断价值。方法：选取EC患者40例作为A组，同期选取子宫良性疾病患者40例作为B组，并同期选取健康体检者40例作为C组，抽取三组患者的血清标本，并检测其血清HE4、NGAL及CA125水平，并对比血清HE4、NGAL和CA125单独检测与联合检测的阳性检出率，且于治疗1个月后检测A组患者血清HE4、NGAL和CA125水平变化。结果：治疗前，A组患者血清HE4、NGAL和CA125水平明显高于B组和C组（P＜0.05）；而B组患者血清HE4、NGAL和CA125水平与C组比较无统计学差异（P＞0.05）；治疗前，A组血清HE4、NGAL和CA125联合检测阳性率（87.50%）明显高于血清HE4、NGAL和CA125单独检测（62.50%、60.00%、67.50%）（P＜0.05）；而B组和C组血清HE4、NGAL和CA125联合检测阳性率与血清HE4、NGAL和CA125单独检测比较无统计学差异（P＞0.05）；治疗后，A组患者血清HE4、NGAL和CA125水平明显低于治疗前（P＜0.05）。结论：血清HE4、NGAL和CA125在EC组织中均明显表达，均可作为EC检测及手术疗效判断标志物，且血清HE4、NGAL和CA125联合检测可明显明显提高EC诊断准确性。
Abstract:
Objective: To investigate the clinical value of serum human epididymal secretory protein E4 (HE4)， neutrophil gelatinase associated lipid carrier protein (NGAL) and human ovarian cancer antigen (CA125) in the detection of endometrial carcinoma (EC).Methods：40 case EC patients as A group， 40 cases of uterine benign disease patients as B group， and 40 healthy subjects were selected as group C， serum samples from three patients， and the detection of serum HE4， NGAL and CA125 levels， and serum HE4， contrast NGAL and CA125 detection and combined detection of the positive rate， and in 1 months after treatment to detect changes in A levels of serum HE4， NGAL and CA125 levels.Results：Before treatment， A group of serum HE4， NGAL and CA125 levels were significantly higher than that of B group and C group (P＜0.05); And no significant difference between B group and CA125 NGAL， serum HE4 level and C group (P＞0.05); A group before treatment， combined detection of serum HE4， NGAL and CA125. The rate (87.50%) was significantly higher than that of serum HE4， NGAL and CA125 respectively (62.50%， 60%， 67.50%) (P＜0.05); And B group and C group serum HE4， combined detection of NGAL and CA125 with the positive rate of serum HE4， NGAL and CA125 detection alone had no significant (P＞0.05); After the treatment. A group of serum HE4， NGAL and CA125 were significantly lower than those before treatment (P＜0.05).Conclusion: Serum HE4， NGAL and CA125 are all expressed obviously in EC tissues. They can be used as markers for EC detection and operation efficacy evaluation. Combined detection of serum HE4， NGAL and CA125 can significantly improve the diagnostic accuracy of EC， so it is worthy of clinical promotion.

参考文献/References:

[1]龙滨，陈琳.CA125和TSH联合检测对诊断子宫内膜癌的价值[J].中国妇幼保健，2016，31(17)：3484-3486.
[2]田龙，黄瑞瑜，张瑜.MRI对子宫内膜癌的诊断及分期应用[J].陕西医学杂志，2015，44(12)：1690-1691.
[3]周颖，廖予妹.联合检测多种分子标志物及血清CA_(125)对子宫内膜癌的临床意义[J].中国妇幼保健，2014，29(12)：1936-1940.
[4]张玉香，任红伟，刘春丽.血清NGAL和CA125联合检测在子宫内膜癌组织中的临床应用[J].海南医学院学报，2015，21(4)：543-546.
[5]李美艳.HE4、OPN及uPA检测对子宫内膜癌患者诊断的临床意义[J].国际肿瘤学杂志，2017，44(5)：351-355.
[6]Giatromanolaki A，Sivridis E，Brekken R，et al.The angiogenic vascular endothelial growth factor/flk-1(KDR) receptor pathway in patients with endometrial carcinoma: prognostic and therapeutic implications[J].Cancer，2015，92(10)：2569-2577.
[7]王美巍，李佩玲.新肿瘤标志物及联合检测诊断子宫内膜癌的研究进展[J].现代肿瘤医学，2016，24(5)：834-837.
[8]谭蓓蓓.血清HCG和CA125联合检测对子宫内膜癌早期诊断的临床意义[J].临床合理用药杂志，2016，9(20)：23-24.
[9]黄生金.血清CA125与CA153联合检测对子宫内膜癌的诊断价值[J].国际检验医学杂志，2013，34(24)：3301-3302.
[10]吴双，耿敬姝.HE4在子宫内膜癌诊断中的应用价值评估[J].肿瘤学杂志，2014，20(11)：955-958.
[11]方旖骅，颜士杰.血清人附睾蛋白4检测对子宫内膜癌诊断的临床意义[J].安徽医学，2015，36(9)：1068-1071.
[12]罗树玲，郑春艳，曹锦慧.血清CA125和HE4检测在子宫内膜癌中的临床意义[J].中国实验诊断学，2016，20(9)：1490-1492.
[13]姚冬梅.HE4研究进展[J].陕西医学杂志，2012，41(12):1676-1677.
[14]林莺莺，陈燕，胡敏华，等.HE4、CA125和CA19-9单项和联合检测在子宫内膜癌诊断中的价值[J].临床检验杂志，2014，32(6)：471-473.
[15]张玉香，任红伟，张波，等.子宫内膜癌患者血清和肿瘤组织中NGAL、NGALR含量及其与凋亡基因的关系[J].海南医学院学报，2015，21(12)：1697-1700.
[16]孙润蛟，金仙玉，刘桂香，等.人附睾分泌蛋白4在子宫内膜癌组织中的表达及临床意义[J].中国医学创新，2016，13(30)：1-7.
[17]徐海.子宫内膜癌组织中NGAL、VEGF-C及CA125的表达及其临床意义[J].中国妇幼保健，2016，31(18)：3728-3729.

更新日期/Last Update: 2018-11-30